Accéder au contenu
Merck

Massively parallel reporter assays of melanoma risk variants identify MX2 as a gene promoting melanoma.

Nature communications (2020-06-03)
Jiyeon Choi, Tongwu Zhang, Andrew Vu, Julien Ablain, Matthew M Makowski, Leandro M Colli, Mai Xu, Rebecca C Hennessey, Jinhu Yin, Harriet Rothschild, Cathrin Gräwe, Michael A Kovacs, Karen M Funderburk, Myriam Brossard, John Taylor, Bogdan Pasaniuc, Raj Chari, Stephen J Chanock, Clive J Hoggart, Florence Demenais, Jennifer H Barrett, Matthew H Law, Mark M Iles, Kai Yu, Michiel Vermeulen, Leonard I Zon, Kevin M Brown
RÉSUMÉ

Genome-wide association studies (GWAS) have identified ~20 melanoma susceptibility loci, most of which are not functionally characterized. Here we report an approach integrating massively-parallel reporter assays (MPRA) with cell-type-specific epigenome and expression quantitative trait loci (eQTL) to identify susceptibility genes/variants from multiple GWAS loci. From 832 high-LD variants, we identify 39 candidate functional variants from 14 loci displaying allelic transcriptional activity, a subset of which corroborates four colocalizing melanocyte cis-eQTL genes. Among these, we further characterize the locus encompassing the HIV-1 restriction gene, MX2 (Chr21q22.3), and validate a functional intronic variant, rs398206. rs398206 mediates the binding of the transcription factor, YY1, to increase MX2 levels, consistent with the cis-eQTL of MX2 in primary human melanocytes. Melanocyte-specific expression of human MX2 in a zebrafish model demonstrates accelerated melanoma formation in a BRAFV600E background. Our integrative approach streamlines GWAS follow-up studies and highlights a pleiotropic function of MX2 in melanoma susceptibility.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting human YY1